RaQualia Pharma Inc.
4579.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥3,543 | ¥3,423 | ¥2,764 | ¥3,142 |
| Short-Term Investments | ¥0 | ¥89 | ¥0 | ¥200 |
| Receivables | ¥549 | ¥715 | ¥1,156 | ¥689 |
| Inventory | ¥185 | ¥172 | ¥171 | ¥168 |
| Other Curr. Assets | ¥97 | ¥55 | ¥174 | ¥147 |
| Total Curr. Assets | ¥4,640 | ¥4,909 | ¥4,483 | ¥4,539 |
| Property Plant & Equip (Net) | ¥480 | ¥526 | ¥549 | ¥529 |
| Goodwill | ¥3,698 | ¥3,766 | ¥3,835 | ¥3,865 |
| Intangibles | ¥36 | ¥35 | ¥34 | ¥37 |
| Long-Term Investments | ¥537 | ¥570 | ¥474 | ¥547 |
| Tax Assets | ¥73 | ¥75 | ¥79 | ¥78 |
| Other NC Assets | ¥55 | ¥55 | ¥57 | ¥60 |
| Total NC Assets | ¥4,879 | ¥5,027 | ¥5,028 | ¥5,117 |
| Other Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥9,519 | ¥9,936 | ¥9,511 | ¥9,655 |
| Liabilities | – | – | – | – |
| Payables | ¥58 | ¥55 | ¥60 | ¥59 |
| Short-Term Debt | ¥589 | ¥590 | ¥590 | ¥582 |
| Tax Payable | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Revenue | ¥0 | ¥73 | ¥156 | ¥186 |
| Other Curr. Liab. | ¥311 | ¥211 | ¥307 | ¥221 |
| Total Curr. Liab. | ¥995 | ¥1,023 | ¥1,226 | ¥1,187 |
| LT Debt | ¥2,267 | ¥2,395 | ¥2,523 | ¥2,651 |
| Deferred Rev, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Tax Liab, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Other NC Liab. | ¥20 | ¥19 | ¥31 | ¥27 |
| Total NC Liab. | ¥2,481 | ¥2,626 | ¥2,785 | ¥2,897 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥0 | ¥289 | ¥309 | ¥288 |
| Total Liabilities | ¥3,476 | ¥3,649 | ¥4,011 | ¥4,085 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥3,241 | ¥3,241 | ¥2,721 | ¥2,721 |
| Retained Earnings | -¥615 | -¥400 | -¥51 | -¥46 |
| AOCI | -¥14 | ¥16 | -¥80 | -¥15 |
| Other Equity | -¥0 | -¥0 | -¥0 | ¥0 |
| Total Equity | ¥6,042 | ¥6,287 | ¥5,500 | ¥5,571 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liab. & Tot. Equity | ¥9,519 | ¥9,936 | ¥9,511 | ¥9,655 |
| Net Debt | -¥687 | -¥438 | ¥349 | ¥92 |